Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

NCT02173301 is registered in ClinicalTrials.gov with Dr. Reddy's Laboratories Limited as lead sponsor.

NCT NCT02173301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02173301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Lead sponsor
Dr. Reddy's Laboratories Limited
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2014
Completion date
August 31, 2015
Enrollment
200 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis